ライフサイエンスコーパス: enzyme-linked immunospot

1 after the treatment course, as determined by enzyme-linked immunospot.

2 by IFN-gamma-specific immunofluorescence and enzyme-linked immunospot.

3 vigorous cytotoxic T lymphocyte response by enzyme-linked immunospot.

4 ononuclear cells (PBMCs), were studied using enzyme-linked immunospot.

5 from 12/12 donors released IFN-gamma (50-300 enzyme-linked immunospots/200,000 T cells) and prolifera

6 Enzyme-linked immunospot analyses confirmed that many of

7 Furthermore, enzyme-linked immunospot analyses demonstrated prominent

8 D4 T-cell epitopes within OMPs, we performed enzyme-linked immunospot analyses for gamma interferon (

9 Immunohistochemical, flow cytometric, and enzyme-linked immunospot analyses of the spleen, kidney,

10 Using enzyme-linked immunospot analysis (ELISPOT) assays, we f

11 IFN-gamma enzyme-linked immunospot analysis demonstrated the prese

12 responses against A20 cells, as assessed via enzyme-linked immunospot analysis in vitro and immune pr

13 Enzyme-linked immunospot analysis reveals that these CTL

14 of IFN-gamma-secreting cytotoxic T cells by enzyme-linked immunospot analysis that may have also fac

15 cells were not detected by immunoglobulin M enzyme-linked immunospot analysis until day 7.

16 ell epitopes were mapped by gamma interferon enzyme-linked immunospot analysis using five overlapping

17 ed subjects not on antiretroviral therapy by enzyme-linked immunospot analysis with 53 peptide pools

18 cancer patients and 18 healthy donors using enzyme-linked immunospot analysis.

19 onor, as determined by tetramer staining and enzyme-linked immunospot analysis.

20 ic CD8(+) T cells were detected by IFN-gamma enzyme-linked immunospot and (51)Cr release assay in loc

21 l responses, as detected by interferon-gamma enzyme-linked immunospot and allo-antibody production, r

22 in BALB/c mice revealed that the DNA induced enzyme-linked immunospot and antigen-specific proliferat

23 A27, B5, L1, and A33, using gamma interferon enzyme-linked immunospot and cytokine flow cytometry ass

24 nd assessed HBV-specific T-cell responses by enzyme-linked immunospot and cytometric bead array.

25 r +/- tumor lysates were tested in gamma-IFN enzyme-linked immunospot and cytotoxicity assays.

26 P. falciparum by performing standardized MBC enzyme-linked immunospot and enzyme-linked immunosorbent

27 However, gamma interferon (IFN-gamma) enzyme-linked immunospot and IFN-gamma/tumor necrosis fa

28 Further, the IFN-gamma enzyme-linked ImmunoSPOT and in vitro 51Cr release assay

29 ses measured principally by gamma interferon enzyme-linked immunospot and neutralization assays were

30 ll responses were characterized by IFN-gamma enzyme-linked immunospot and whole blood intracellular c

31 Preliminary studies using enzyme-linked immunospot and Winn assays suggested that

32 esponder cell frequency and interferon-gamma enzyme-linked immunospot, and antibodies were measured b

33 (as measured by interferon gamma production, enzyme-linked immunospot, and CD137 upregulation assays)

34 IAP, as revealed by proliferation, tetramer, enzyme-linked immunospot, and cytotoxicity analysis.

35 Results from functional analyses by DTH, enzyme-linked immunospot, and immunohistofluorescence as

36 ukin 2, 4, 5, and 6 were counted by means of enzyme-linked immunospot, and SFC counts were compared b

37 response to HCV antigens were enumerated by Enzyme Linked Immunospot Assay.

38 ysis), and more IFN-gamma-secreting cells by enzyme-linked immunospot assay (1460 vs 280 IFN-gamma sp

39 ls developed neutralizing antibodies and low enzyme-linked immunospot assay (E-SPOT) titers against S

40 Enzyme-linked immunospot assay (ELISPOT) analysis of pso

41 ssed by ex vivo gamma interferon (IFN-gamma) enzyme-linked immunospot assay (ELISPOT) and antibody as

42 LSA-1 and TRAP peptides were assessed by the enzyme-linked immunospot assay (ELISPOT) and enzyme-link

43 to detect autoreactive responses when using enzyme-linked immunospot assay (ELISPOT) and enzyme-link

44 ere detected by interferon-gamma (IFN-gamma) enzyme-linked immunospot assay (ELISPOT) assays using th

45 Gamma interferon (IFN-gamma) measured by enzyme-linked immunospot assay (ELISPOT) at multiple tim

46 racellular IFN-gamma staining, and IFN-gamma enzyme-linked immunospot assay (ELISPOT) indicated that

47 We used flow cytometry and enzyme-linked immunospot assay (ELISPOT) to examine B-ce

48 We used the ex vivo IFN-gamma enzyme-linked immunospot assay (ELISpot) to track T cell

49 antigen-specific IFN-gamma production in an enzyme-linked immunospot assay (ELISPOT).

50 after allogeneic BMT using gamma-interferon enzyme-linked immunospot assay (ELISPOT).

51 tion, and measured antibody-secreting cells (enzyme-linked immunospot assay [ELISPOT]) as an early ma

52 phisms with cellular (interferon [IFN] gamma enzyme-linked immunospot assay [ELISPOT]) immune respons

53 ted in these animals by the gamma interferon enzyme-linked immunospot assay against pools of short ov

54 specific CD8+ CTL responses were detected by enzyme-linked immunospot assay against several NY-BR-1 p

55 Cultured enzyme-linked immunospot assay analysis demonstrated tha

56 lar sensitization was detected by performing enzyme-linked immunospot assay analysis for cytokines in

57 ce data of specific genes were combined with enzyme-linked immunospot assay analysis of critical epit

58 Enzyme-linked immunospot assay analysis of peripheral T-

59 rus-specific T-cell responses by means of an enzyme-linked immunospot assay and antibody responses by

60 A antibody-secreting B cells was analyzed by enzyme-linked immunospot assay and by analysis of Epstei

61 Enzyme-linked immunospot assay and ELISA analysis were r

62 (+) T cells, as detected by interferon gamma enzyme-linked immunospot assay and flow cytometry, were

63 he vaccine and drifted A(H3N2) viruses by an enzyme-linked immunospot assay and flow cytometry.

64 By gamma interferon enzyme-linked immunospot assay and intracellular cytokin

65 ion assay) and T cell responses (measured by enzyme-linked immunospot assay and intracellular cytokin

66 ain SCC-derived antigens using the IFN-gamma enzyme-linked immunospot assay and intratumor (IT) and c

67 at multiple time points by interferon-gamma enzyme-linked immunospot assay and was correlated to the

68 tified memory responses measured by cultured enzyme-linked immunospot assay as well as in vitro inter

69 e measured in 9 patients by interferon-gamma enzyme-linked immunospot assay at 3 time points within 1

70 in the blood by gamma interferon (IFN-gamma) enzyme-linked immunospot assay at select time points; ho

71 re likely to have a positive response to ASC enzyme-linked immunospot assay at the late time point th

72 a virus were detected by an interferon gamma enzyme-linked immunospot assay but had no clear relation

73 analyzed in the gamma interferon (IFN-gamma)-enzyme-linked immunospot assay by using synthetic overla

74 f CNS-derived mononuclear cells by IFN-gamma enzyme-linked immunospot assay confirmed the selection o

75 An Ag-specific B cell enzyme-linked immunospot assay confirmed these results a

76 FITC/DNFB skin painting and subsequent enzyme-linked immunospot assay demonstrated that flow-so

77 1 subject, antigen-specific interferon-gamma enzyme-linked immunospot assay detected an immunogenic d

78 e further confirmed by the results of CD4(+) enzyme-linked immunospot assay for interferon (IFN)-gamm

79 ng was performed using a CEA peptide and the enzyme-linked immunospot assay for interferon gamma prod

80 , and GAD65 peptides) were measured by IL-17 enzyme-linked immunospot assay in patients with new-onse

81 berculosis strain H37Rv as a stimulant in an enzyme-linked immunospot assay in sensitized individuals

82 ), and in healthy control subjects (n=10) by enzyme-linked immunospot assay in the presence and absen

83 validation cohort were measured by IFN-gamma enzyme-linked immunospot assay or intracellular cytokine

84 ed a 10- to 40-fold increase in HIV-specific enzyme-linked immunospot assay responses compared to tho

85 mmunosorbent assay titers, and EnvA-specific enzyme-linked immunospot assay responses, and these resp

86 Enzyme-linked immunospot assay results indicated that th

87 IFN-gamma enzyme-linked immunospot assay showed that the D2V (71-7

88 y higher numbers of spot-forming cells in an enzyme-linked immunospot assay than did T cells primed w

89 t gamma interferon production, determined by enzyme-linked immunospot assay to at least one of the th

90 To address this, we used an enzyme-linked immunospot assay to define the frequency a

91 We used an enzyme-linked immunospot assay to determine the frequenc

92 1 transgenic NOD mice in an interferon-gamma enzyme-linked immunospot assay to identify autoantigenic

93 D8 T cell responses were quantified using an enzyme-linked immunospot assay to measure interferon-gam

94 MI responses by interferon gamma (IFN-gamma) enzyme-linked immunospot assay using 3 recombinant HCV p

95 eens of immunized mice by a gamma interferon enzyme-linked immunospot assay using peptides derived fr

96 gamma interferon-producing cells detected by enzyme-linked immunospot assay was increased (P < 0.01 f

97 An IFN-gamma enzyme-linked immunospot assay was used to determine the

98 Using enzyme-linked immunospot assay we found higher frequenci

99 asured by gamma interferon and interleukin 2 enzyme-linked immunospot assay were significantly higher

100 MPO-specific T cells were quantified by enzyme-linked immunospot assay with additional Treg cell

101 mined by intracellular cytokine staining and enzyme-linked immunospot assay) and produced anti-PR8 an

102 ss I Gag-tetramer staining, gamma interferon-enzyme-linked immunospot assay, and cytotoxic T-cell ass

103 ays, antigen-specific interferon (IFN)-gamma enzyme-linked immunospot assay, and enzyme-linked immuno

104 ern blot, delayed type hypersensitivity, and enzyme-linked immunospot assay, and reduced the number o

105 d multiparameter flow cytometric sorting and enzyme-linked immunospot assay, demonstrate that anti-Ga

106 ific T cells, enumerated by gamma interferon enzyme-linked immunospot assay, did not appear until 2 w

107 y-secreting cells (ASC) in blood measured by enzyme-linked immunospot assay, the antibody in lymphocy

108 s-specific CD4 responses by gamma interferon enzyme-linked immunospot assay, using 410 overlapping pe

109 An interferon-gamma enzyme-linked immunospot assay, using peptide pools span

110 assay and/or ex vivo interferon (IFN)-gamma enzyme-linked immunospot assay, was documented in 45.5%

111 Using an enzyme-linked immunospot assay, we evaluated immunoglobu

112 Using flow cytometric analysis and enzyme-linked immunospot assay, we examined peripheral n

113 a interferon-secreting cells, as detected by enzyme-linked immunospot assay, were obtained in respons

114 cing CD4(+) T cell responses, as assessed by enzyme-linked immunospot assay, were significantly more

115 )-4-secreting cells were determined using an enzyme-linked immunospot assay, which demonstrated that

116 Viral loads, CD4(+) T-cell counts, and enzyme-linked immunospot assay-determined anti-HIV-1 CD8

117 tibody-secreting cells were enumerated using enzyme-linked immunospot assay.

118 us peptides via interferon-gamma (IFN-gamma) enzyme-linked immunospot assay.

119 assays, intracelluar cytokine staining, and enzyme-linked immunospot assay.

120 l responses were assayed by interferon-gamma enzyme-linked immunospot assay.

121 ymphocyte proliferation and interferon gamma enzyme-linked immunospot assay.

122 racheobronchial lymph nodes as determined by enzyme-linked immunospot assay.

123 and in 22 (73%) of 30 vaccine recipients by enzyme-linked immunospot assay.

124 emory responses were evaluated by IFN- gamma enzyme-linked immunospot assay.

125 ulated memory B cells were detected using an enzyme-linked immunospot assay.

126 , and IL-6 cytokines as measured by cytokine enzyme-linked immunospot assay.

127 producing gamma interferon when analyzed by enzyme-linked immunospot assay.

128 red in peripheral blood mononuclear cells by enzyme-linked immunospot assay.

129 producing B cells could still be detected by enzyme-linked immunospot assay.

130 body assay, and an interferon gamma-specific enzyme-linked immunospot assay.

131 5, 7, and 14 postgrafting, as measured by an enzyme-linked immunospot assay.

132 +) T lymphocytes were induced as analyzed by enzyme-linked immunospot assay.

133 h nodes, lungs, and Peyer's patches using an enzyme-linked immunospot assay.

134 -positive, HLA A2-positive individuals in an enzyme-linked immunospot assay.

135 pond to HIV-1 peptides in a gamma interferon enzyme-linked immunospot assay.

136 T-cell responses by using a gamma interferon enzyme-linked immunospot assay.

137 ed in the various tissues of GalT-/- mice by enzyme-linked immunospot assay.

138 mic lymphoid tissues were evaluated using an enzyme-linked immunospot assay.

139 -seropositive individual using the IFN-gamma enzyme-linked immunospot assay.

140 body- forming cells were determined using an enzyme-linked immunospot assay.

141 cells measured before challenge by cultured enzyme-linked immunospot assay.

142 and dsDNA antibody-secreting cells (ASCs) by enzyme-linked immunospot assay.

143 ral suppression assay (VSA) and an IFN-gamma enzyme-linked immunospot assay.

144 red by enzyme-linked immunosorbent assay and enzyme-linked immunospot assay.

145 s were detected by gamma interferon-specific enzyme-linked immunospot assay.

146 B cell Ig isotype switching was measured by enzyme-linked immunospot assay.

147 mmunity to SHIV89.6 peptides was measured by enzyme-linked immunospot assay; strong responses to Gag

148 ent assays (ELISA) titers, and EnvA-specific enzyme-linked immunospot assays (ELISPOT) responses.

149 mune responses were measured by tetramer and enzyme-linked immunospot assays against gp100 and MART-1

150 e compared by standardized interferon- gamma enzyme-linked immunospot assays among 250 unvaccinated i

151 this limitation by using two-color cytokine enzyme-linked immunospot assays and computer-assisted im

152 Enzyme-linked immunospot assays confirmed this high freq

153 Enzyme-linked immunospot assays detected precursor CTL s

154 Spleen cells were phenotyped, and enzyme-linked immunospot assays for autoantibody-produci

155 cluding MHC class I tetramer binding assays, enzyme-linked immunospot assays for IFN-gamma production

156 cells that recognize EBV-latent antigens in enzyme-linked immunospot assays for interferon gamma sec

157 BL/6 beta-gal transgenic skin were tested in enzyme-linked immunospot assays for recall responses to

158 c CD8(+)-T-cell responses were determined by enzyme-linked immunospot assays in 150 HIV-infected indi

159 s shown by cytotoxicity and interferon gamma enzyme-linked immunospot assays in six of nine patients.

160 immune-sensitization using the B and T-cell enzyme-linked immunospot assays may identify CMV-sensiti

161 eins were used to screen 15 normal donors in enzyme-linked immunospot assays of gamma interferon rele

162 pping peptides and gamma interferon-specific enzyme-linked immunospot assays of peripheral blood mono

163 Results of enzyme-linked immunospot assays of the immunized mice re

164 were assessed using interferon (IFN)- gamma enzyme-linked immunospot assays on peripheral blood mono

165 Interferon-gamma (IFN-gamma) enzyme-linked immunospot assays on peripheral blood mono

166 Proliferation and gamma interferon enzyme-linked immunospot assays using peripheral blood l

167 Interferon gamma (IFN-gamma) enzyme-linked immunospot assays were performed before an

168 Enzyme-linked immunospot assays were performed to confir

169 Enzyme-Linked ImmunoSpot assays yielded parallel results

170 production in mixed lymphocyte reaction and enzyme-linked immunospot assays, respectively.

171 nterferon (IFN)-gamma and interleukin (IL)-5 enzyme-linked immunospot assays, respectively.

172 By use of enzyme-linked immunospot assays, the percentages of memo

173 s, trans-vivo delayed-type hypersensitivity, enzyme-linked immunospot assays, the use of antigen rece

174 ic T cells were measured by interferon-gamma enzyme-linked immunospot assays, using recombinant vacci

175 wild-type sequence was also demonstrated by enzyme-linked immunospot assays.

176 A-matched peptides by using gamma interferon enzyme-linked immunospot assays.

177 aining, and fine mapping in interferon-gamma enzyme-linked immunospot assays.

178 pol regimen, as measured by gamma interferon enzyme-linked immunospot assays.

179 T-cell responses as measured using IFN-gamma enzyme-linked immunospot assays.

180 DNA cells by IFN-gamma-secretion measured in enzyme-linked immunospot assays.

181 ls in both cytotoxicity assays and IFN-gamma enzyme-linked immunospot assays.

182 the lamina propria of the small intestine by enzyme-linked immunospot assays.

183 lected at selected times were quantitated by enzyme-linked immunospot assays.

184 cell responses, measured by interferon gamma enzyme-linked immunospot assays.

185 ld in-tube test (ELISA), and T-SPOT.TB test (enzyme-linked immunospot) at 17 centers in 11 European c

186 Enzyme-linked immunospots, cytotoxicity assays as well a

187 phore linked immunosorbent assay (FLISA) and enzyme linked immunospotting (ELISPOT).

188 This result was supported by enzyme-linked immunospot (ELISPOT) analyses indicating c

189 erferon (IFN-gamma) and interleukin-5 (IL-5) enzyme-linked immunospot (ELISPOT) analyses were used to

190 Using high resolution enzyme-linked immunospot (ELISPOT) analysis, we have rev

191 )-producing CD8(+) T cells, as determined by enzyme-linked immunospot (ELISPOT) analysis.

192 isease, CMV-specific interferon (IFN)- gamma enzyme-linked immunospot (ELISPOT) and CD8(+) and CD4(+)

193 the same protein following RSV infection by enzyme-linked immunospot (ELISPOT) and intracellular cyt

194 tricted epitope using interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) and intracellular cyt

195 Acute Hepatitis C (ATAHC), using HCV peptide enzyme-linked immunospot (ELISPOT) and multiplex in vitr

196 ctly ex vivo by gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay (P = 2 x 10(-10

197 tive allo-HCT recipients with a CMV-specific enzyme-linked immunospot (ELISPOT) assay and for CMV inf

198 epitopes measured by interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay and HLA/peptide

199 nd lytic antigens by interferon (IFN)- gamma enzyme-linked immunospot (ELISPOT) assay and interleukin

200 responses, as indicated by gamma interferon enzyme-linked immunospot (ELISPOT) assay and intracellul

201 zed mice as determined by using quantitative enzyme-linked immunospot (ELISpot) assay and intracellul

202 Interferon-gamma enzyme-linked immunospot (ELISPOT) assay and tetramer an

203 We have developed a gamma interferon enzyme-linked immunospot (ELISPOT) assay for evaluation

204 ere screened by gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay for HLA class I

205 With an enzyme-linked immunospot (ELISPOT) assay for interferon

206 A highly sensitive enzyme-linked immunospot (ELISPOT) assay for single cell

207 ned using a sensitive interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) assay in 187 Caucasia

208 IgG-secreting cells were detected by enzyme-linked immunospot (ELISPOT) assay in cell suspens

209 Quantification of interferon (IFN)-gamma by enzyme-linked immunospot (ELISPOT) assay is currently us

210 compared the HIV-specific ex vivo IFN-gamma enzyme-linked immunospot (ELISPOT) assay responses of 19

211 Gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay responses targe

212 nstrated VV-specific interferon (IFN)- gamma enzyme-linked immunospot (ELISPOT) assay responses; 21 (

213 to HSV-2 directly, ex vivo, we developed an enzyme-linked immunospot (ELISPOT) assay that utilized p

214 We developed and assessed a sensitive enzyme-linked immunospot (ELISPOT) assay to detect T cel

215 nized NZB/NZW mice were analyzed in vitro by enzyme-linked immunospot (ELISpot) assay to determine T

216 ecific responses in the vaccinia virus-based enzyme-linked immunospot (Elispot) assay using a panel o

217 The enzyme-linked Immunospot (ELISPOT) assay was used to det

218 y full-proteome gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay were restricted

219 hort-term T-lymphocyte cell lines, IFN-gamma enzyme-linked immunospot (ELISPOT) assay with peripheral

220 responses were detected by use of a modified enzyme-linked immunospot (ELISpot) assay with recombinan

221 body-secreting cells (ASCs) were measured by enzyme-linked immunospot (ELISPOT) assay, and antibody r

222 Tetramer staining, enzyme-linked immunospot (ELISPOT) assay, and cytotoxici

223 Here the enzyme-linked immunospot (ELISPOT) assay, intracellular

224 mulation and assessed IFN-gamma secretion by enzyme-linked immunospot (Elispot) assay.

225 ed Env-specific immunoglobulin G (IgG) in an enzyme-linked immunospot (ELISPOT) assay.

226 were determined by using an interferon-gamma enzyme-linked immunospot (ELISpot) assay.

227 recombinant vaccinia vectors was measured by enzyme-linked immunospot (ELISPOT) assay.

228 pressed HIV-1 proteins in a gamma interferon-enzyme-linked immunospot (Elispot) assay.

229 and in vitro by mixed leukocyte reaction and enzyme-linked immunospot (ELISPOT) assay.

230 quantified for all subjects in an IFN-gamma enzyme-linked immunospot (ELISpot) assay.

231 creting T cells in the hosts was measured by enzyme-linked immunospot (ELISPOT) assay.

232 r flow cytometry, flow antibody binding, and enzyme-linked immunospot (ELISpot) assay.

233 rs with the same peptide pools in a cultured enzyme-linked immunospot (ELISPOT) assay.

234 8-27) pentamer staining and CD8(+) IFN-gamma enzyme-linked immunospot (ELISPOT) assay.

235 as assessed by gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay.

236 using peripheral blood mononuclear cells in enzyme-linked immunospot (Elispot) assays and using CTL

237 In this study, sensitive enzyme-linked immunospot (elispot) assays have been util

238 detected by interferon (IFN) gamma and IL-2 enzyme-linked immunospot (ELISPOT) assays in 50% and 40%

239 pecific IFN-gamma responses were detected by enzyme-linked immunospot (ELISPOT) assays in all subject

240 However, validated enzyme-linked immunospot (ELISpot) assays of influenza-s

241 ivity to escape variant peptides in standard enzyme-linked immunospot (ELISPOT) assays predicts the r

242 tantial CD8(+) T cell responses by IFN-gamma enzyme-linked immunospot (ELISPOT) assays to all 11 of t

243 In this study, we performed quantitative enzyme-linked immunospot (ELISPOT) assays to measure loc

244 We used single-cell resolution enzyme-linked immunospot (ELISPOT) assays to study, dire

245 CMV immunoglobulin G (IgG) avidity and CMV enzyme-linked immunospot (ELISpot) assays were employed

246 In interferon-gamma (IFN-gamma) enzyme-linked immunospot (ELISPOT) assays, antiviral res

247 Using IFN-gamma and interleukin (IL)-2 enzyme-linked immunospot (ELISpot) assays, we analyzed t

248 Using tetramer and enzyme-linked immunospot (ELISPOT) assays, we have obser

249 es in enzyme immunoassay, proliferation, and enzyme-linked immunospot (ELISpot) assays.

250 um-release and confirmatory interferon-gamma enzyme-linked immunospot (ELISPOT) assays.

251 N-gamma) responses to the peptide epitope in enzyme-linked immunospot (ELISPOT) assays.

252 (MHC) tetramer staining and gamma interferon enzyme-linked immunospot (ELISPOT) assays.

253 unique to the seasonal or pandemic strain by enzyme-linked immunospot (ELISpot) assays.

254 interferon-gamma (IFN-gamma) release by CD4 enzyme-linked immunospot (ELISPOT) at one or more time p

255 lass II cellular immunity was analyzed using enzyme-linked immunospot (ELISPOT) by testing recipient

256 The enzyme-linked immunospot (Elispot) gamma interferon assa

257 ysaccharide cellular immunity, measured with enzyme-linked immunospot (ELISPOT) interferon gamma rele

258 tionated HIV-1 gag-specific interferon gamma enzyme-linked immunospot (ELISpot) response 4 weeks afte

259 Enzyme-linked immunospot (ELISpot) showed no interferon-

260 ll responses were assessed in proliferation, enzyme-linked immunospot (ELISPOT), interferon (IFN)-gam

261 pping HCV peptides and 6 proteins by ex vivo enzyme-linked immunospot (ELISpot), intracellular cytoki

262 were compared with three functional assays: enzyme-linked immunospot (Elispot), intracellular cytoki

263 Analyses included IFN-gamma enzyme-linked immunospot (ELISPOT), reverse transcriptio

264 T-cell responses as determined by IFN-gamma enzyme-linked immunospot (ELISPOT), tetramer, and cytoto

265 peripheral blood lymphocyte gamma interferon enzyme-linked immunospot (ELISPOT), tetramer, and intrac

266 r tissues and analyzed by flow cytometry and enzyme-linked ImmunoSpot (ELISpot).

267 unoglobulin (Ig) A antibody-secreting cells (enzyme-linked immunospot [ELISPOT] assay), IgG serologic

268 alpha, or CD40L), and more ex vivo IFN-gamma enzyme-linked immunospots (ELISPOTs) than did the RTS,S/

269 of 500 to 1,000 gamma interferon (IFN-gamma) enzyme-linked immunospots (ELISPOTS)/10(6) peripheral bl

270 T-cell responses were studied by enzyme-linked immunospot for interferon-gamma.

271 change between pre-study and postvaccination enzyme-linked immunospot frequency of purified CD8 T-cel

272 s (VZV) T-cell responses by interferon-gamma enzyme-linked immunospot (IFN-gamma ELISPOT) and VZV ant

273 sorbent assay (gpELISA) and interferon-gamma enzyme-linked immunospot (IFN-gamma ELISPOT), blood samp

274 cell proliferative responses, and cytokines (enzyme-linked immunospot) in 48 subjects with unresolved

275 Enzyme-linked immunospot, intracellular cytokine stainin

276 ce was assessed by skin and heart grafts and enzyme-linked immunospot, intracellular cytokine, and mi

277 esponses of neonates and adults, we used the enzyme-linked immunospot method to measure the frequenci

278 llograft recipients was evaluated ex vivo by enzyme-linked immunospot, mixed lymphocytes reaction, cy

279 Using interferon-gamma enzyme-linked immunospot, Mtb39-specific CD8+ T lymphocy

280 ers and T-cell immunity to AAV, validated by enzyme-linked immunospot on the second day after gene in

281 = 0.0043), IFN-gamma production measured by enzyme-linked immunospot (P < 0.0001), and multiplex cyt

282 sed by enzyme-linked immunosorbent assay and enzyme-linked immunospot performed at baseline and from

283 Furthermore, positive enzyme-linked immunospot reactions to belagenpumatucel-L

284 gnitude of the SIV-specific gamma interferon enzyme-linked immunospot response.

285 A hierarchy was observed in enzyme-linked immunospot responses (with the strongest r

286 ys developed high-frequency gamma interferon enzyme-linked immunospot responses against BCG purified

287 animals developed vigorous gamma interferon enzyme-linked immunospot responses and moderate prolifer

288 We assessed KSHV-specific interferon- gamma enzyme-linked immunospot responses in a cohort of 154 in

289 pment of neutralizing antibody and IFN-gamma enzyme-linked immunospot responses to AAV1 capsid at day

290 gnitude and the breadth of interferon- gamma enzyme-linked immunospot responses were inversely correl

291 IFN- gamma enzyme-linked immunospot responses were significantly di

292 interferon (IFN)-gamma secretion, IFN-gamma enzyme-linked immunospot responses, and direct ex vivo i

293 strong ex vivo tetramer and interferon gamma enzyme-linked immunospot responses, and endogenous expre

294 d II were used to stimulate interferon-gamma enzyme-linked immunospot responses.

295 e ELISA (1.31 cases per 100 person-years) or enzyme-linked immunospot result (1.78 cases per 100 pers

296 ated cell sorter, mixed lymphocyte reaction, enzyme-linked immunospot, signaling studies, and a rat m

297 anti-Salmonella mucosal immune responses by enzyme-linked immunospot studies.

298 ear cells were tested using interferon-gamma enzyme-linked immunospot T assays measuring the response

299 Postchallenge enzyme-linked immunospot values for Gag and Env as well

300 terial Ag-specific CD8+ T cells by IFN-gamma enzyme-linked immunospot was 5-10-fold lower than the pr